Inicio
Autor Juan Carlos Restrepo Gutiérrez
|
Comentario :
Médico Internista Hepatólogo, Hospital Pablo Tobón Uribe
|
Documentos disponibles escritos por este autor (110)
Refinar búsquedaO-6 EXPLORING THE IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOL- ASSOCIATED HEPATITIS IN LATIN AMERICA / Juan Carlos Restrepo Gutiérrez
Título : O-6 EXPLORING THE IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOL- ASSOCIATED HEPATITIS IN LATIN AMERICA Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Autor Fecha de publicación : 2024 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Resumen : Introduction and Methods Severe alcohol-associated hepatitis (AH) is frequently associated with higher infection risk. This study aimed to assess the impact of infections in patients with AH in a multinational cohort in Latin America. Materials and Methods Multicenter prospective cohort study including patients with AH (2015-2022). We recorded clinical information, and the impact of infections was assessed using competing-risk models. Results We included 511 patients from 24 centers in 8 countries (Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, and Peru). The mean age was 50.1±11.9 years, 426 (83.9%) were men, 264 (58.2%) had a previous diagnosis of cirrhosis, and the median MELD at diagnosis was 24.6 [19.6–30.6] points. Out of the total, 25.9% died, and only 3.7% underwent liver transplantation during follow-up. Also, 44.5% of patients developed an infection. Of them, 50.9% presented with infection at admission, 30.8% developed an infection during hospitalization, and 18.3% presented an infection in both situations. The most common localizations at admission were pulmonary (32.4%), urinary tract (33.1%), spontaneous bacterial peritonitis (15.9%), and cutaneous (9.7%). The main localizations during hospitalization were pulmonary (34.4%), urinary tract (25.8%), spontaneous bacterial peritonitis (14.0%), and bacteremia (8.6%%). The incidence of multidrug-resistant (MDR) organisms was 11.2% at admission and 10.3% during hospitalization, while the incidence of extensively drug-resistant (XDR) organisms was 1.4% and 4.7%, respectively. The presence of infection was associated with higher mortality (sub-distribution hazard ratio [sHR] 1.92, 95%CI:1.56–2.37; p Mención de responsabilidad : Luis Antonio Díaz, Francisco Idalsoaga, Gustavo Ayares, Jorge Arnold, Katherine Maldonado, María Ayala, Diego Perez, Jaime Gomez, Rodrigo Escarate, Eduardo Fuentes, Juan Pablo Roblero, Blanca Norero, Raul Lazarte, José Antonio Velarde, Janett Jacobo, Jacqueline Córdova, Fátima Higuera-de-la-Tijera, Jesús Varela, Scherezada Mejía, Rita Silva, Cristina Melo, Roberta C. Araujo, Gustavo Henrique Pereira, Claudia Couto,fernando Bessone, Mario Tanno, Gustavo Romero, Manuel Mendizabal, Sebastián Marciano, Gonzalo Gomez,Melisa Dirchwolf, Pedro Montes, Patricia Guerra, Geraldine Ramos, Juan Carlos Restrepo, Enrique Carrera, Mayur Brahmania, Ashwani Singal, Ramón Bataller, Vijay Shah, Patrick S. Kamath,Marco Arrese,Juan Pablo Arab Referencia : Annals of Hepatology Volume 29, Supplement 1, February 2024, 101256 DOI (Digital Object Identifier) : 10.1016/j.aohep.2023.101256 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S1665268123003599 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis O-6 EXPLORING THE IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOL- ASSOCIATED HEPATITIS IN LATIN AMERICA [documento electrónico] / Juan Carlos Restrepo Gutiérrez, Autor . - 2024.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Resumen : Introduction and Methods Severe alcohol-associated hepatitis (AH) is frequently associated with higher infection risk. This study aimed to assess the impact of infections in patients with AH in a multinational cohort in Latin America. Materials and Methods Multicenter prospective cohort study including patients with AH (2015-2022). We recorded clinical information, and the impact of infections was assessed using competing-risk models. Results We included 511 patients from 24 centers in 8 countries (Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, and Peru). The mean age was 50.1±11.9 years, 426 (83.9%) were men, 264 (58.2%) had a previous diagnosis of cirrhosis, and the median MELD at diagnosis was 24.6 [19.6–30.6] points. Out of the total, 25.9% died, and only 3.7% underwent liver transplantation during follow-up. Also, 44.5% of patients developed an infection. Of them, 50.9% presented with infection at admission, 30.8% developed an infection during hospitalization, and 18.3% presented an infection in both situations. The most common localizations at admission were pulmonary (32.4%), urinary tract (33.1%), spontaneous bacterial peritonitis (15.9%), and cutaneous (9.7%). The main localizations during hospitalization were pulmonary (34.4%), urinary tract (25.8%), spontaneous bacterial peritonitis (14.0%), and bacteremia (8.6%%). The incidence of multidrug-resistant (MDR) organisms was 11.2% at admission and 10.3% during hospitalization, while the incidence of extensively drug-resistant (XDR) organisms was 1.4% and 4.7%, respectively. The presence of infection was associated with higher mortality (sub-distribution hazard ratio [sHR] 1.92, 95%CI:1.56–2.37; p Mención de responsabilidad : Luis Antonio Díaz, Francisco Idalsoaga, Gustavo Ayares, Jorge Arnold, Katherine Maldonado, María Ayala, Diego Perez, Jaime Gomez, Rodrigo Escarate, Eduardo Fuentes, Juan Pablo Roblero, Blanca Norero, Raul Lazarte, José Antonio Velarde, Janett Jacobo, Jacqueline Córdova, Fátima Higuera-de-la-Tijera, Jesús Varela, Scherezada Mejía, Rita Silva, Cristina Melo, Roberta C. Araujo, Gustavo Henrique Pereira, Claudia Couto,fernando Bessone, Mario Tanno, Gustavo Romero, Manuel Mendizabal, Sebastián Marciano, Gonzalo Gomez,Melisa Dirchwolf, Pedro Montes, Patricia Guerra, Geraldine Ramos, Juan Carlos Restrepo, Enrique Carrera, Mayur Brahmania, Ashwani Singal, Ramón Bataller, Vijay Shah, Patrick S. Kamath,Marco Arrese,Juan Pablo Arab Referencia : Annals of Hepatology Volume 29, Supplement 1, February 2024, 101256 DOI (Digital Object Identifier) : 10.1016/j.aohep.2023.101256 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S1665268123003599 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002184 AC-2024-037 Archivo digital Producción Científica Artículos científicos Disponible
Título : O-7 CURRENT PRACTICE OF LIVER TRANSPLANTATION IN LATIN AMERICAN COUNTRIES: AN ALEH INTEREST GROUP SURVEY 2023 Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Autor Fecha de publicación : 2024 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Resumen : Introduction and Objectives Little is known about current practice of liver transplantation (LT) in Latin American countries (LATAM). This study aimed to describe LT activity, immunosuppression protocols and policies regarding prophylaxis of cytomegalovirus (CMV) infection and hepatitis B virus (HBV) recurrence in different active LATAM centers. Materials and Methods A web-based survey with 20 questions regarding LT practice was sent to all members of ALEH LT SIG in December 2022. Results 22 centers performing 35 [5-160] LT per year from Brazil (n=5), Argentina (n=4), Chile (n=4), Ecuador (n-2), Mexico (n=2), Colombia (n=1), Costa Rica (n=1), Peru (n=1), Dominican Republic (n=1) and Uruguay (n=1) answered the survey. Tacrolimus, mycophenolate and prednisone was the main immunosuppressive regimen employed by most (72%) centers and 81% of them referred basiliximab use for induction therapy in selected patients. Tailoring of immunosuppression was universally accepted, particularly in autoimmune hepatitis (AIH) (59%), hepatocellular carcinoma (54%) kidney dysfunction (77%) and primary biliary cirrhosis (33%). Weaning of corticosteroids at three, six and 12 months after LT was reported, respectively, by 41%, 36% and 23% of the centers, but policy for lifelong corticosteroid use in AIH-transplanted subjects was commonly observed (90%). Just four centers are currently performing protocol liver biopsies, while 18 of them are considering liver biopsy prior to steroid pulse therapy. HBIG and nucleos(t)ide analogs are used in most instances (73%) for HBV recurrence prevention, whereas CMV infection prophylaxis was shown to vary sharply across centers. Of note, all but two of them referred major changes in LT practice over the years due to economical restraints. Conclusions Compliance with standard of care recommendations for management of LT was reported by most centers. Heterogeneity in practices regarding HBV infection recurrence and CMV prophylaxis may reflect local financial restraints and point to the importance of developing ALEH guidelines to encourage LT activity in LATAM. Mención de responsabilidad : Paulo Bittencourt, Liana Codes, Adrian Gadano, Alejandra Villamil, Alfeu de Medeiros Fleck Jr, Álvaro Urzua, Debora Raquel Terrabuio, Eira Cerda, Graciela Elia Castro Narro, Ignacio Roca, John Abad González, Josefina Pages, Juan Carlos Restrepo Gutierrez, Leonardo de Lucca Schiavon, Mario Uribe, Martin Padilla, Norma Marlene Perez Figueroa, Pablo Coste Murillo, Raquel Stucchi, Ricardo Chong, Rodrigo Wolff, Victoria Mainardi, Rodrigo Zapata. Referencia : Annals of Hepatology Volume 29, Supplement 1, February 2024, 101257 DOI (Digital Object Identifier) : 10.1016/j.aohep.2023.101257 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S1665268123003605 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis O-7 CURRENT PRACTICE OF LIVER TRANSPLANTATION IN LATIN AMERICAN COUNTRIES: AN ALEH INTEREST GROUP SURVEY 2023 [documento electrónico] / Juan Carlos Restrepo Gutiérrez, Autor . - 2024.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Resumen : Introduction and Objectives Little is known about current practice of liver transplantation (LT) in Latin American countries (LATAM). This study aimed to describe LT activity, immunosuppression protocols and policies regarding prophylaxis of cytomegalovirus (CMV) infection and hepatitis B virus (HBV) recurrence in different active LATAM centers. Materials and Methods A web-based survey with 20 questions regarding LT practice was sent to all members of ALEH LT SIG in December 2022. Results 22 centers performing 35 [5-160] LT per year from Brazil (n=5), Argentina (n=4), Chile (n=4), Ecuador (n-2), Mexico (n=2), Colombia (n=1), Costa Rica (n=1), Peru (n=1), Dominican Republic (n=1) and Uruguay (n=1) answered the survey. Tacrolimus, mycophenolate and prednisone was the main immunosuppressive regimen employed by most (72%) centers and 81% of them referred basiliximab use for induction therapy in selected patients. Tailoring of immunosuppression was universally accepted, particularly in autoimmune hepatitis (AIH) (59%), hepatocellular carcinoma (54%) kidney dysfunction (77%) and primary biliary cirrhosis (33%). Weaning of corticosteroids at three, six and 12 months after LT was reported, respectively, by 41%, 36% and 23% of the centers, but policy for lifelong corticosteroid use in AIH-transplanted subjects was commonly observed (90%). Just four centers are currently performing protocol liver biopsies, while 18 of them are considering liver biopsy prior to steroid pulse therapy. HBIG and nucleos(t)ide analogs are used in most instances (73%) for HBV recurrence prevention, whereas CMV infection prophylaxis was shown to vary sharply across centers. Of note, all but two of them referred major changes in LT practice over the years due to economical restraints. Conclusions Compliance with standard of care recommendations for management of LT was reported by most centers. Heterogeneity in practices regarding HBV infection recurrence and CMV prophylaxis may reflect local financial restraints and point to the importance of developing ALEH guidelines to encourage LT activity in LATAM. Mención de responsabilidad : Paulo Bittencourt, Liana Codes, Adrian Gadano, Alejandra Villamil, Alfeu de Medeiros Fleck Jr, Álvaro Urzua, Debora Raquel Terrabuio, Eira Cerda, Graciela Elia Castro Narro, Ignacio Roca, John Abad González, Josefina Pages, Juan Carlos Restrepo Gutierrez, Leonardo de Lucca Schiavon, Mario Uribe, Martin Padilla, Norma Marlene Perez Figueroa, Pablo Coste Murillo, Raquel Stucchi, Ricardo Chong, Rodrigo Wolff, Victoria Mainardi, Rodrigo Zapata. Referencia : Annals of Hepatology Volume 29, Supplement 1, February 2024, 101257 DOI (Digital Object Identifier) : 10.1016/j.aohep.2023.101257 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S1665268123003605 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002185 AC-2024-038 Archivo digital Producción Científica Artículos científicos Disponible La piel como reflejo de trastornos hepáticos subyacentes / Juan Carlos Restrepo Gutiérrez en Hepatología, Vol. 5 No. 1 (2024)
Título : La piel como reflejo de trastornos hepáticos subyacentes Otros títulos : The skin as a reflection of underlying liver disorders Tipo de documento : texto impreso Autores : Juan Carlos Restrepo Gutiérrez, Autor Fecha de publicación : 2024 Artículo en la página : p. 11-12 Idioma : Español (spa) DOI (Digital Object Identifier) : https://doi.org/10.59093/27112330.108 En línea : https://doi.org/10.59093/27112330.108 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis
in Hepatología > Vol. 5 No. 1 (2024) . - p. 11-12[Artículo] La piel como reflejo de trastornos hepáticos subyacentes = The skin as a reflection of underlying liver disorders [texto impreso] / Juan Carlos Restrepo Gutiérrez, Autor . - 2024 . - p. 11-12.
Idioma : Español (spa)
in Hepatología > Vol. 5 No. 1 (2024) . - p. 11-12
DOI (Digital Object Identifier) : https://doi.org/10.59093/27112330.108 En línea : https://doi.org/10.59093/27112330.108 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis
Título : Avances y logros editoriales de la revista Hepatología Otros títulos : Editorial progress and achievements of the journal Hepatología Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2022 Títulos uniformes : Hepatología Idioma : Español (spa) Mención de responsabilidad : Juan Carlos Restrepo-Gutiérrez Referencia : Hepatología ; 3(1): 11-12, 2022. DOI (Digital Object Identifier) : 10.52784/27112330.144 Derechos de uso : CC BY-NC-ND En línea : https://revistahepatologia.com/index.php/hepa/article/view/44 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Avances y logros editoriales de la revista Hepatología = Editorial progress and achievements of the journal Hepatología [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2022.
Obra : Hepatología
Idioma : Español (spa)
Mención de responsabilidad : Juan Carlos Restrepo-Gutiérrez Referencia : Hepatología ; 3(1): 11-12, 2022. DOI (Digital Object Identifier) : 10.52784/27112330.144 Derechos de uso : CC BY-NC-ND En línea : https://revistahepatologia.com/index.php/hepa/article/view/44 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001835 AC-2022-007 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-007Adobe Acrobat PDF
Título : COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2022 Títulos uniformes : Journal of Translational Autoimmunity Idioma : Inglés (eng) Palabras clave : Autoimmune hepatitis COVID-19 SARS-CoV-2 AstraZeneca ChAdOx1 nCoV-19 AZD1222 Resumen : Autoimmunity following COVID-19 vaccination has been reported. Herein, a 79-year-old man with clinical and immunological features of autoimmune hepatitis type 1 after ChAdOx1 nCoV-19 vaccination is presented. Clinical manifestations rapidly remitted after the instauration of immunomodulatory management. This case, together with a comprehensive review of the literature, illustrates the association between COVID-19 vaccines and the development of autoimmune conditions. Mención de responsabilidad : Laura Camacho-Domínguez, Yhojan Rodríguez, Fernando Polo, Juan Carlos Restrepo Gutierrez, Elizabeth Zapata, Manuel Rojas, Juan-Manuel Anaya Referencia : J Transl Autoimmun. 2022;5:100140. DOI (Digital Object Identifier) : 10.1016/j.jtauto.2022.100140 PMID : 35013724 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589909022000016 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2022.
Obra : Journal of Translational Autoimmunity
Idioma : Inglés (eng)
Palabras clave : Autoimmune hepatitis COVID-19 SARS-CoV-2 AstraZeneca ChAdOx1 nCoV-19 AZD1222 Resumen : Autoimmunity following COVID-19 vaccination has been reported. Herein, a 79-year-old man with clinical and immunological features of autoimmune hepatitis type 1 after ChAdOx1 nCoV-19 vaccination is presented. Clinical manifestations rapidly remitted after the instauration of immunomodulatory management. This case, together with a comprehensive review of the literature, illustrates the association between COVID-19 vaccines and the development of autoimmune conditions. Mención de responsabilidad : Laura Camacho-Domínguez, Yhojan Rodríguez, Fernando Polo, Juan Carlos Restrepo Gutierrez, Elizabeth Zapata, Manuel Rojas, Juan-Manuel Anaya Referencia : J Transl Autoimmun. 2022;5:100140. DOI (Digital Object Identifier) : 10.1016/j.jtauto.2022.100140 PMID : 35013724 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589909022000016 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001779 AC-2022-001 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-001Adobe Acrobat PDF
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
PermalinkPermalink
